Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,000.5 Cr
verified against source
Revenue YoY
32.8%
reported change
EBITDA
₹188.9 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Indegene delivered a landmark Q4 FY26 with revenue crossing ₹1,000 crore for the first time, up 32.8% YoY, and full-year revenue of ₹3,515 crore (+23.6% YoY). Growth was driven by strong deal momentum, including a tectonic engagement with the largest customer in Germany and a $10M+ ACV omni-channel win. Adjusted EBITDA margin contracted ~150bps due to planned investments in AI, talent, and acquisitions (Bioarm, Cake), but management expects margins to recover to historical levels by H2 FY27. PAT was impacted by a one-time ₹20.3 crore provision for a US class action settlement. The pipeline entering FY27 is stronger and more diversified, with GenAI solutions gaining traction across commercial and medical segments. Key risk: margin recovery may be delayed if investment intensity persists beyond planned timelines.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects adjusted EBITDA margins to revert to earlier higher levels in the second half of FY27 as current investments get absorbed.
- The tectonic win in Germany with the largest customer is expected to drive revenue growth, crossing the $50 million threshold.
- Tectonic has customer validation with two pilots converting to long-term engagements and is set to be a material growth driver.
- Positive impact from higher cash balances, stable yields, lower amortization, and absence of one-time items will boost PAT.
Risks flagged
- Management plans to reinvest any margin upside above the historical range, which could delay margin expansion beyond H2 FY27.
- A ₹20.3 crore provision for a TCPA lawsuit was booked; while management believes it's a one-off, further liabilities cannot be ruled out.
- Top 20 customers contribute ~72% of revenue; any loss or slowdown in a key account could materially impact growth.
- Analyst raised concern that LLMs could eventually commoditize domain expertise; management argued defensibility through proprietary data and regulatory nuance.
Key quotes
- Indegene is not an IT services company that happens to serve life sciences. Indegene is a strategic operating partner for the life science industry.
- We are not providing formal revenue guidance. What I will say is this. Our customer portfolio is growing in both depth and breadth and the outside top 20 segment is growing faster.
- We believe that we are on track to improve our profitability and EBITDA margins in FY27 and the second half of FY27 will see us revert back to the earlier levels of higher margins.
Research modules